Human pluripotent stem cell (PSC)–derived cardiomyocytes (CMs) are of high interest for use in drug testing, heart disease modeling, and therapeutic applications. Therefore, standardized protocols for the efficient generation of CMs are needed. Even though several protocols for cardiac differentiation have been published, the majority of them have to be adjusted for each stem cell clone, e.g., by titration of small molecule and cytokine concentrations, in order to obtain the optimal differentiation efficiency and cell yield. Moreover, lot-to-lot variations of media components also influence the outcome of differentiation. These protocol optimizations are costly and time consuming. In order to circumvent these limitations, we developed a cardiac differentiation medium, the StemMACS™ CardioDiff Kit, enabling robust and standardized cardiac differentiation, without the need for media adjustments.
time point of differentiation, morphological changes could be observed. On day 1, cell clusters became visible, which disappeared on day 3 of differentiation. From days 4 to 6, cardiac clusters started to form. First contracting cells were observed on days 6–8 of differentiation. This new workflow protocol allows for robust, highly efficient, and scalable generation of CMs within
less than 10 days of differentiation, thereby solving several technical issues related to the generation of PSCderived CMs.
Related products:
Order no. | Product | Size | Remarks |
130-125-289 (NEW) | StemMACS CardioDiff Kit XF, human | for 48 assays | fast differentiation of human pluripotent stem cells (PSCs) into cardiomyocytes. |
130-125-287 (NEW) | StemMACS Cardiac Cultivation Medium XF, human | 500 mL | maintained PSC-derived cardiomyocytes |
130-109-558 | StemMACS Cryo-Brew | 50 mL | an animal component-free, chemically defined media formulation for cryopreservation under xeno- and serum-free conditions |
Standardized generation of human pluripotent stem cell–derived cardiomyocytes
